Biote's Q2 Loss Reveals Deep Wounds from Hormone Pellet Recall

IRVING, TX – August 05, 2026 – Hormone optimization company Biote is grappling with the severe and prolonged consequences of a product recall, posting a significant net loss and declining revenue for the second quarter of 2026. The financial downturn, directly linked to a voluntary recall of hormone pellets initiated in January, has forced the company to slash its full-year financial forecast and has sent its stock tumbling, raising critical questions about its operational resilience and path to recovery.

In its latest earnings report, Biote (NASDAQ: BTMD) revealed total revenue fell 9.5% year-over-year to $44.2 million. The core of its business, procedure revenue, suffered a steeper 13.9% decline to $30.3 million. The company swung to a net loss of $7.4 million, a stark reversal from the $3.9 million in net income reported in the same quarter last year. Adjusted EBITDA, a key measure of profitability, plummeted to $5.6 million from $15.2 million a year ago.

“Over the past year Biote has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe position the Company to achieve sustainable procedure revenue growth,” said Bob Peterson, Biote’s interim Chief Executive Officer, in a statement that sought to reassure investors. “While not yet evident in our financial results, these foundational improvements have strengthened the core of our business and enhanced our resiliency, which we expect will drive improved financial performance in the second half.”

The Anatomy of a Recall

The source of Biote's current troubles traces back to January 26, 2026, when its wholly-owned 503B manufacturing subsidiary, Asteria Health, initiated a voluntary recall of specific lots of its compounded hormone pellets. The recall was triggered by the potential presence of metal particulate matter in pellets shipped nationwide over an eight-month period.

The U.S. Food and Drug Administration (FDA) subsequently classified it as a Class II recall, a designation indicating that use of the product may cause temporary or medically reversible adverse health consequences, with the probability of serious adverse effects being remote. While not the most severe classification, the recall of an implantable product for potential contamination created a significant operational and reputational crisis.

Initially, the company appeared to underestimate the fallout, suggesting the recall would not materially impact its ability to supply its network of certified practitioners. However, the financial results from the first half of 2026 tell a different story. After estimating a $1.7 million revenue impact in the first quarter, the company now reports the recall’s hit to procedure revenue escalated to $3.3 million in the second quarter alone, contributing to lower procedure volumes and what the company termed “elevated clinic attrition.”

A Crisis of Confidence and Supply

The recall's impact extends far beyond the direct costs. It has strained Biote's relationship with its network of certified practitioners—the very foundation of its business model. The company acknowledged that its sales team had to redirect efforts to support clinics affected by the recall, leading to “slower productivity from new clinics.” This diversion of resources and the underlying product quality issue risk eroding the trust that is crucial for retaining and growing its network in a competitive market.

Compounding the issue is a severe supply chain disruption. The recall exposed the vulnerability of Biote’s reliance on Asteria Health. The subsidiary’s contribution to Biote’s shipped pellets collapsed from over 50% in late 2025 to just 30% through the first half of 2026. This forced Biote to source replacement products from third-party suppliers at higher costs, which, combined with reduced manufacturing efficiencies at Asteria, squeezed its gross profit margin down to 65.4% from 71.6% a year prior.

This vertical integration strategy, intended to be a long-term margin enhancer, has instead become a single point of catastrophic failure. While the company is focused on restoring Asteria’s capacity, the episode serves as a stark case study on the risks of consolidating manufacturing without robust contingency plans, especially in the highly regulated healthcare sector.

Navigating the Fallout

Amid the turmoil, Biote’s leadership is attempting a strategic reset. Peterson, who was named interim CEO in late May, is now tasked with navigating the company through the crisis. He stressed that the company is entering the “next phase of our strategic roadmap,” which will focus on enhancing the practitioner experience and accelerating sales productivity.

However, the immediate road ahead looks difficult. The company has materially revised its full-year 2026 guidance, now expecting revenue above $175 million and Adjusted EBITDA above $25 million. This is a significant reduction from the guidance of over $190 million in revenue and $38 million in Adjusted EBITDA issued just a few months ago. Critically, Biote no longer expects to return to year-over-year procedure revenue growth in the second half of 2026, a clear admission that the recall's disruption will have a longer tail than previously anticipated.

While the company’s dietary supplements segment provided a lone bright spot with 5.7% growth to $11.4 million, it was not nearly enough to offset the damage to its core hormone therapy business.

Wall Street's Verdict and an Uncertain Path Forward

Investors reacted swiftly and negatively to the news. Biote’s stock fell more than 6% in after-hours trading following the August 5th announcement, continuing a punishing year that has seen its value decline by nearly 45%. The Q2 results widely missed Wall Street estimates, which had projected higher revenue and a modest profit, not a $7.4 million loss.

While some analysts maintain a cautiously optimistic long-term view, near-term price targets have been trimmed as the market digests the depth of the operational challenges. The company's struggles present a potential opening for competitors like EvexiPEL and SottoPelle in the growing but scrutinized market for bioidentical hormone replacement therapy.

As Biote works to rebuild its manufacturing capabilities and regain the trust of its practitioner network, its journey will be closely watched. The company's ability to execute its strategic turnaround will determine whether this period marks a temporary setback or a more permanent shift in its market position.